Our findings suggest a tumor‐suppressive role for METTL3 in the early stages of HCC, emphasizing the importance of understanding the dynamic role of epigenetic regulation in tumorigenesis and targeted therapy. This evidence concerns the gene METTL3 and hepatocellular carcinoma.